Proteomics reveals the importance of the dynamic redistribution of the subcellular location of proteins in breast cancer cells by Pinto, G et al.
 1 
 
Proteomics Reveals the Importance of the Dynamic Redistribution 
of the Subcellular Location of Proteins in Breast Cancer Cells 
 
 
 
 
Gabriela Pinto‡, Abdulrab Ahmed M. Alhaiek and 
Jasminka Godovac-Zimmermann* 
 
 
 
Division of Medicine, University College London, Centre for Nephrology, Royal Free  
Campus, Rowland Hill Street, London NW3 2PF, UK, EU 
‡Present address: Department of Pharmacy, University of Naples Federico II, Via D. Montesano 
49, 80131 Napoli, Italy 
 
 
*Corresponding author: Prof Jasminka Godovac-Zimmermann,  
email:j.godovac-zimmermann@ucl.ac.uk 
 
 
Keywords: MCF-7 cells • breast cancer •subcellular protein location•nucleus 
•cytoplasm •SILAC• quantitative proteomics • mass spectrometry • estrogen 
receptor • protein trafficking 
 2 
 
 
Abstract 
At the molecular level living cells are enormously complicated complex adaptive 
systems in which intertwined genomic, transcriptomic, proteomic and metabolic 
networks all play a crucial role. At the same time, cells are spatially heterogeneous 
systems in which subcellular compartmentalization of different functions is 
ubiquitous and requires efficient cross-compartmental communication. Dynamic 
redistribution of multitudinous proteins to different subcellular locations in response 
to cellular functional state is increasingly recognized as a crucial characteristic of 
cellular function that seems to be at least as important as overall changes in protein 
abundance. Characterization of the subcellular spatial dynamics of protein 
distribution is a major challenge for proteomics and recent results with MCF7 breast 
cancer cells suggest that this may be of particular importance for cancer cells.  
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Cancer and complexity 
Our oldest description of cancer was discovered in Egypt and dates back to 3000 BC. 
Breast cancer was described in the Edwyn Smith Papyrus with a written verdict: 
“There is no treatment” [1]. Much of the anatomical and clinical knowledge obtained 
in the 16th and 17th centuries was followed by progress in pathology and 
experimental research in cancer treatment and scientific surgery in the 18th and 19th 
centuries. Today cancer still constitutes a major scientific endeavour occupying 
chemists, biologist, geneticists and physicists [101]. Cancers have been found in 
everything from coral to budgerigars and dinosaurs [102]. Despite at least 3 013 022 
publications on cancer (1818-2014) and large-scale “omics” studies for humanity, 
cancer is still the “Emperor of all maladies”[2]. Although mortality levels are lower 
than for infectious/parasitic and heart disease [103], cancer remains a fascinating 
scientific challenge, fundamentally due to its fearsome complexity. 
A major complexity problem in cancer is occasioned by the fact that heterogeneity is 
a ubiquitous feature of tumors. Carcinogenesis is not a single step process and 
initiation through proliferation and metastasis stages are thought to be dynamically 
influenced by accumulation of a large number of genetic mutations [3]. Each round 
of cell division may cause increased instability and complexity of the genome that 
enhance tumor progress [3]. The enigmatic heterogeneity within the same kind of 
tumor makes manifestation of the disease unpredictable and greatly complicates 
clinical diagnosis via characteristics such as morphological features, cellular 
biomarkers, hormonal receptors, gene expression, propensity to metastasize and 
recurrence potentials [4,5]. It has been suggested that cancer should be regarded as a 
chaotic process [6] and there is some recent evidence for stochastic changes in breast 
cancer cell lines [7]. Although progress is being made, advances in effective disease 
diagnosis, management and prognosis would be achieved by further understanding of 
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the basis of this heterogeneity. 
In the age of large-scale “omics” that followed on the completion of human genome 
sequencing, the development of ever more powerful DNA sequencing methods, of 
DNA-microarray technology and of proteomics led to two major large-scale methods 
for investigation of breast cancer and other diseases: (1) large-scale genome-wide-
association-strategies (GWAS) that involve screening of large number of patients to 
identify genetic mutations correlated with disease [8,9], and (2) extensive 
investigation of differential gene expression via transcriptomics and proteomics [10]. 
The large-scale GWAS strategies have been found to have limitations, e.g. in 
complex diseases many common disease-correlated mutations are neither necessary 
nor sufficient for the disease and often seem only to be deleterious in the context of 
the genome/proteome of an individual [11]. This has led to proposals that such data 
needs to be integrated with transcriptomic, proteomic, metabolomic and clinical 
information to develop ‘functional-network-based’ conceptual models of normal 
function, disease, diagnostics and therapy [12,13]. Large-scale screening of mRNA 
levels showed that multiple and extensive changes in mRNA levels are commonly 
seen in breast cancer [14-17]. More recently such studies have been extended to 
involvement of micro-RNAs [18] and epigenetic modulation of chromatin [19]. 
There were important reasons [20] to complement this work with high throughput 
proteomics methods, including that protein abundance may be different than 
transcript abundance and that for genetic variation, translation and protein stability 
may be more determinant for protein abundance than transcript levels [21]. Recent 
work on tumor samples suggests that transcriptomics and proteomics measurements 
of total abundance monitor different aspects of cancer cell function and provide 
highly complementary information [22]. 
These methods are accompanied by very large numbers of more conventional but 
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increasingly powerful molecular and cell biology studies that focus on specific local 
features within highly complex cellular networks and which are collected and 
collated in data bases such as GO, REACTOME, etc. For example, cancer-related 
eukaryotic cell proliferation is known to involve complex molecular choreography of 
mitogens that stimulate cell growth, membrane receptors, their signaling pathways, 
and downstream effectors of cell division and cellular metabolic state [15,23,24]. 
Very complex cellular signalling systems modulate cancer cell function through 
post-translational modifications such as phosphorylation [25] and 
methylation/acetylation [26].  Large-scale proteomics detection of PTMs like 
phosphorylation or acetylation has been crucial in this area [27]. 
A key feature long known from molecular and cell biology, but so far often ignored 
in many large-scale studies, is that cellular function is highly dependent on the spatial 
distribution of many cellular components, ranging over metabolites, low molecular 
weight signaling molecules (e.g. GTP, Ca2+, NADH, ROS), proteins, lipids, tRNA 
[28], etc. An emerging theme, that is the focus of this report, is that the subcellular 
distribution of proteins is dynamic and context-dependent, that proteins may have 
different functions at different subcellular locations, that the dynamic distributions 
are a crucial feature of cellular function and that perturbation of spatial control may 
be an important feature of cancer. Indeed, we suggest that dynamic alterations of 
subcellular spatial distribution of proteins is at least equally important to changes in 
total protein abundance in cellular function.  
Indications for the importance of dynamic subcellular distribution of proteins. 
There are innumerable conventional cell biology studies that demonstrate 
functionally relevant subcellular translocation of specific individual proteins, even 
for proteins that were once regarded as “housekeeping” proteins [29-31]. The 
different subcellular translocation of the isoforms of hexokinases, HKI and HKII, is 
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known to be a mechanism of cellular regulation addressing the cell to catabolic or 
anabolic glucose utilization both in proliferating cells or in cancer cells [32]. Two 
isoforms of pyruvate kinases, PKM1 and PKM2, have diverse involvement in 
metabolic pathways. These include the shuttling of pyruvate preferentially to lactate 
dehydrogenase instead of to mitochondria that underlines the major role of the 
cytoplasmic PKM2 isoform in tumor progression [33], translocation into the nucleus 
that occurs in response to different apoptotic stimuli [34], and participation in nuclear 
transcription complexes in response to hypoxia [35]. Another example of crucial 
subcellular redistribution is BRCA1, well known for its nuclear-cytoplasmic 
trafficking in breast cancer [36]; recently, its redistribution to the cytoplasm in 
malignant breast cancer tissues has been supposed to be a defence mechanism of the 
cell probably associated with a more intense cellular apoptotic activity [37]. 
However, study of expression and subcellular localization for single proteins or small 
groups of proteins may often limit understanding of cellular mechanisms because of 
the complex networking of biological systems. Moreover the high number of 
moonlighting proteins with different functions in various subcellular compartments 
as well as massive spatio-temporal and condition-dependent redistribution of proteins 
makes understanding even more complicated. 
Methods for Global Determination of Protein Distributions.  
There are a very large number of proposed methods for monitoring protein location 
within cells. These have been extensively reviewed recently [38]. The vast majority 
of these methods involve the tagging of proteins with some sort of detectable marker. 
This can limit their applicability to global monitoring of dynamic protein 
distribution, but they may be highly attractive as techniques for confirming results 
for specific proteins obtained with global methods. We do not consider these 
methods further here and refer readers to the above review. 
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At present there seem to be three technologies that are capable of global monitoring. 
For lower eukaryotes such as yeast, it is possible to use molecular biology methods 
to introduce markers on a genome-wide scale. Such methods have been used to show 
that about 4-5% of yeast proteins are subject to subcellular translocation under 
hypoxia [39] and to show that at least a third of yeast mitochondrial proteins have 
additional subcellular locations outside of mitochondria [40]. For higher eukaryotes 
and study of issues such as cancer, there currently seem to be only two appropriate 
technologies available, each of which has strengths and disadvantages.  
Antibody-based proteomics includes techniques that are often used to detect/evaluate 
one or a few proteins such as immunohistochemistry (IHC), enzyme-linked immune-
sorbent assay (ELISA), western blot, and immunoprecipitation (IP). The large-scale 
platforms include tissue microarrays (TMAs) and reverse phase protein arrays 
(RPPAs) that can provide the tools and the strategies to generate systematic analysis 
using specific antibodies. However, a common limitation is that antibodies must be 
available and are greatly variable in terms of sensitivity and specificity [41]. 
Furthermore, a quantitative approach cannot be easily robust; the order of 
magnitudes in the proteome is widely variable [42]. 
The other global method is MS-based analysis of subcellular fractions, which is the 
main focus in the following text. This has been used for some time to investigate 
protein content of selected subcellular organelles [38], but often without 
consideration of dynamic changes in their protein content. This method seems to 
have greater dynamic range and greater ability to accurately quantitate moderate 
changes in abundance at a given subcellular location compared to the antibody 
methods. These features can be crucial, e.g., in the detection of trace amounts of 
cytosolic metabolic enzymes involved in nuclear functions or in the measurement of 
changes in cellular function by coordinated, moderate changes of many proteins in 
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complex networks.  
Workflows for MS-based quantitative shotgun subcellular proteomics using 
differential isotope labelling by metabolic incorporation or chemical labelling are 
now well established (Fig.1). The huge raw data files obtained from high-resolution 
mass spectrometers requires a powerful processing platform with quantitative 
proteomics software and subsequently rigorous procedures for result validation to 
avoid erroneous protein identification and to obtain statistically reliable quantitative 
information. An important consideration with this method is the reliability of protein 
distributions based on the breakage and fractionation of cells and this is considered in 
further detail below. 
Static Studies of the Global Subcellular Distribution of Proteins. 
The development of methods for subcellular fractionation to gain more insight into 
protein function has been emphasized since at least 1946 on the basis of the idea that 
"The physiology of the cell cannot be fully understood unless we succeed in 
determining the constitution of its parts..." [43]. The by now large body of work on 
the proteomes of specific subcellular organelles has often been dominated by the 
concept that highly pure organelle preparations are required [38]. This focus has 
carried over to a number of studies of the overall global distribution of proteins to 
multiple subcellular locations under static (non-stimulated) conditions, where 
emphasis has often been placed on determining the location of a protein. While 
highly purified organelles allow determination of what might be termed “permanent 
resident” proteins, we believe that this limited focus constrains elucidation of cellular 
function. Much as the original central dogma of molecular biology (one gene implies 
one mRNA implies one protein) has been well and truly superseded, so there has 
long been strong evidence that the often unconsciously assumed corollary (one 
protein implies one cellular location implies one function) is equally superseded. The 
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cell biology literature is full of thousands of examples of proteins with multiple 
subcellular locations and multiple functions. The GO database contains annotations 
to multiple subcellular locations for 36% of human proteins and this is certainly an 
underestimate. We consider that the most important proteins for coordination of 
cellular function over spatially and functionally inhomogeneous cells are likely to 
usually be those that are not “permanent residents”, but rather translocate to different 
subcellular locations/functions in response to cellular state. These may be 
“peripheral” proteins in any given subcellular organelle and may often be lost during 
stringent preparation of highly purified organelles. To give a specific example, 
nuclear respiratory factor 2 (NRF2) is a critical transcription factor for response to 
oxidative stress [44]. It is normally present in the cytoplasm complexed with its 
inhibitor KEAP1 and tethered to the outside of mitochondria by interactions of this 
complex with PGAM5 [45], which places NRF2 in proximity to sources of reactive 
oxygen species (ROS) from the mitochondrial respiratory chain. A crucial aspect of 
NRF2 function is its translocation from this peripheral mitochondrial location to the 
nucleus under conditions of oxidative stress. Hence, in looking at cancer and other 
cells there hence seem to be three crucial questions. (1) how many such multiply 
located/potentially translocating proteins are there? (2) How many proteins are 
shared between functionally essential organelles such as the nucleus and 
mitochondria (this section)? (3) how can we reliably identify and verify the 
functional importance of the dynamic redistribution of such proteins (next section)?  
In a paper published by Qattan et al [46], three crucial features of the subcellular 
distribution of proteins in MCF7 breast cancer cells were established: (a) large 
numbers of proteins are distributed over multiple subcellular locations, (b) there is 
substantial variation between different proteins in their relative amounts in different 
locations, but many proteins have appreciable quantities in various locations, and (c) 
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those proteins widely distributed over different locations are also those with currently 
annotated participation in the widest variety of functional processes. In this work, a 
quantitative proteomic method was used to study the static distribution of subcellular 
proteins in MCF7 breast cancer cells by combination of sucrose density gradient 
subcellular fractionation and tandem-MS-based shotgun proteomics analysis. Four 
separated portions of the sucrose gradient that roughly corresponded to four major 
organelle compartments (cytosol, plasma membrane, endoplasmic reticulum and 
mitochondrion) were subjected to detailed analysis. Stringent controls of the degree 
of purification/contamination/reproducibility of the gradient fractions were applied 
and the relative amounts of proteins localized in one or the other cellular 
compartment measured. A strong linear correlation was found between the relative 
abundance of each protein and the spectral counts of tryptic peptides, as already 
demonstrated by others [47,48]. Thus, spectral counts, calculated by the integration 
of the normalization by Scaffold software and the use of normalized spectral 
abundance factors (NSAF), the latter for counterbalancing the spectral contribution 
of larger proteins, were used as directly corresponding to relative abundance of 
characteristic proteins in the label-free quantification experiments [46,49]. Lower 
abundance proteins with only one assigned peptide or small numbers of counts were 
excluded from the analysis. Different proteins showed different abundance patterns 
over the four compartment (Fig. 2C) and these patterns provided evidence that the 
presence of proteins in multiple locations could not be due to artefacts of the sucrose 
gradient fractionation (Fig. 2D). Each protein was characterized by one or more 
(protein, location, abundance) data points. For 2184 proteins, the 4638 data points 
(an average of 2.1 locations per protein) were used to calculate apparent mole 
fraction distributions of the proteins over 1-4 of the cellular compartments. The 
allowed space for mole fraction distribution was widely occupied (Fig. 2E), 
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indicating good sampling and systematic dispersion of many proteins over multiple 
locations with appreciable abundance in the different locations. As an overall result, 
the data was consistent with detection of 46.7% of the 2184 proteins in multiple 
subcellular locations, this being a lower limit because of the sampling properties of 
spectral counting [46]. Examination of the biological processes in which these 
proteins have been implicated suggested correlation between multiple subcellular 
locations and multiple functional roles [46].  
Similar methods were subsequently applied to the partitioning of proteins between 
the nucleus and mitochondria of MCF7 cells [49]. Western blot analysis of proteins 
constitutively present in mitochondria, the nucleus or other cytoplasmic organelles 
was used to validate the reproducibility of the fractionation procedures prior to MS 
analysis (Figure 3A). For instance, the detection of marker proteins in the expected 
N, M or C subcellular preparations {mitochondria: SDHB, MT-ND1; nucleus: 
ORC2; Golgi apparatus: KDEL; endoplasmic reticulum: ERN1, nucleus and 
cytoplasm: HDAC} confirmed the recovery, reproducibility and purity level of 
fractions used for MS analysis (Figure 3A). 
Following the MS analysis, the subcellular localization attributed to functionally 
interesting proteins can be further confirmed by Western blot analysis (Figure 3B). 
Many functionally interesting proteins were found to have multiple locations, e.g. 
“mitochondrial” proteins (MT-CO2, CYC1, ATP5B, PCK2, SDHA) were observed in 
both the nucleus and mitochondria, in agreement with the MS results. Overall, 985 
proteins were found to be common to mitochondria and the nucleus in MCF7 cells 
[49]. This is a large number compared to previous studies of highly purified 
mitochondria/nuclei, which we believe reflects the stripping of important proteins by 
stringent organelle purification methods, e.g. NRF2 or the hexose kinases (HK1, 
HK2) from the glycolysis enzymatic cascade that are known to shuttle between 
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mitochondria and nuclei in functional roles that determine the metabolic fate of 
glucose and are thought to be crucial to cancer metabolism [50].  
As noted above collation of results in databases such as GO, LOCATE and iLOC-
EUK [38] of large numbers of more conventional cell biology measurements are also 
consistent with multi-site location of high percentages of cellular proteins. 
Monitoring by antibody methods is also converging on this conclusion [51]. 
This brings us to the third critical question noted above: (3) how can we reliably 
identify and verify the functional importance of the dynamic redistribution of such 
proteins? 
Global Dynamics of Subcellular Protein Distribution. 
There are by now a number of studies of dynamic changes in the proteome of 
subcellular organelles using MS-based methods. These were reviewed recently [38]. 
Particularly notable have been several studies of expression levels and subcellular 
localization of endogenous proteins in HeLa cells [52,53] and viral infections [54]. In 
the following we limit discussion to several recent SILAC differential labelling 
studies using a “subcellular spatial razor” approach that are consistent with the 
conceptual framework outlined above: nucleo-ctyoplasmic trafficking of proteins 
following engagement of cell cycle checkpoints for DNA replication [55] or 
exposure to oxidative stress [56] (in human fibroblasts) as well as the response of 
MCF7 breast cancer cells to estrogen stimulation [57].  
Tandem-mass spectrometry-based shotgun proteomics now allows the rapid, accurate 
and highly sensitive identification and quantification of several thousand proteins 
from complex biological samples. The variability caused by pre-MS steps has meant 
that the development of a reliable method for quantitative analysis is still considered 
challenging [58]. However, careful attention to the sources of variability can produce 
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data with a high degree of accuracy and reproducibility [46,49,55-57]. Software 
capable of dealing flexibly and efficiently with quantitative analysis of massive data 
sets, such as MaxQuant [58,59] and Perseus, are an essential requirement. In recent 
studies of the subcellular nucleo-cytoplasmic protein abundance changes for human 
IMR90 fibroblasts following mild tert-butyl peroxide (TBP) oxidative stress [56] or 
following cell cycle arrest at the origin activation checkpoint for DNA replication 
[55], as well as for MCF7 breast cancer cell following exposure to estrogen (E2) 
[57], 12-16 large data sets were processed in parallel with MaxQuant and Perseus. 
The processed data for the unfractionated total cell lysate (T), the nucleus-enriched 
samples (N), and the corresponding nucleus-depleted samples (C) in three replicates 
monitored large numbers of proteins. For example, this included 4386 different 
proteins for estrogen-stimulated MCF7 cells, (3604 reliably quantified according to 
stringent selection criteria [57]) and 3589 proteins for oxidatively stressed human 
IMR90 fibroblasts [56]. For each protein, the corresponding SILAC ratios provided 
measures of the changes in the total cellular abundance (St), or in the nuclear (Sn) or 
cytoplasmic (Sc) compartmental abundance. For the two studies of IMR90 
fibroblasts, the distribution profiles of the SILAC ratios (Sn, Sc and St) showed typical 
Gaussian scatter and outlier analysis such as the Significance B score used in 
MaxQuant could be used to select proteins showing significant changes in total or 
compartmental abundance. Good reproducibility over the replicates for the SILAC 
ratios indicated that with careful sample preparation, reliable, global, dynamic 
protein quantification of different subcellular compartments is possible [56,57].  
The subcellular spatial razor formulation can distinguish between changes in total 
protein abundance (St) and redistribution (Sn/Sc) to/from a target organelle (e.g. the 
nucleus). For all three of the systems so far analyzed with this framework, correlation 
between changes in total abundance and in subcellular nuclear/cytoplasmic 
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redistribution has been found to be low, i.e. changes in compartmental abundance do 
not simply mirror changes in total protein abundance [56,57]. The orthogonal basis 
set {St, Sc/St, Sn/St} for the three measured SILAC ratios separates changes in total 
protein abundance (St) from a distribution plane (Sc/St, Sn/St) that reflects the 
redistribution of a protein. Conservation of mass (highly reproducible subcellular 
fractionation and no differential protein losses between stimulated/unstimulated 
samples during MS sample preparation) requires that the data points lie in 2 
quadrants corresponding to N → C or C → N redistribution of the protein (Fig. 4A) 
and provides a convenient formulation for visualizing/evaluating the reliability of the 
compartmental changes [56,57]. The 3D spatial razor model allows characterization 
of both total and compartmental changes in protein abundance for each individual 
protein (Fig. 4B,C). For instance, the analysis of datasets for estradiol-stimulated 
MCF7 cells showed N → C redistribution of NHP2L1, AGR3, and ERP29 proteins 
accompanied by different changes in their total abundance, as well as marked N → C 
nuclear redistribution of EZR and SUB1 (PC4) with little or no change in total 
abundance as a result of cellular information transfer between different subcellular 
locations upon estradiol stimulation (Fig. 4B) [57]. Similarly, for oxidative stress of 
IMR90 cells, eight subunits of the CCT protein folding complex showed a substantial 
C → N redistribution while proliferating cell nuclear antigen (PCNA) showed an 
opposite N → C redistribution (Fig. 4C), both with a little or no change in total 
abundance and suggestive of “catalytic” transfer of information between different 
subcellular compartments [56]. 
An important feature of the subcellular spatial razor formulation is that it is 
overdetermined and explicitly includes conservation of mass in the quantitative 
evaluations [56,57]. This offers new perspectives for checking the selectivity of the 
detected changes and for evaluation of any effects of “impurity” of the subcellular 
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fractions used in the MS analyses. For example, consistent with the idea that many 
proteins are dispersed over multiple subcellular locations, the nuclear preparation 
analysed in the oxidative stress experiments on IMR90 cells contained 371 proteins 
annotated by GO to mitochondria, only 147 of which were currently also annotated 
to the nucleus by GO. However, only a small proportion of these “mitochondrial” 
proteins showed any change in their fraction in the nucleus in response to oxidative 
stress (Fig. 5) and similar changes in a small proportion of the nuclear proteins was 
observed for those annotated to endoplasmic reticulum, plasma, membrane, the Golgi 
apparatus, lysosomes, endosomes and peroxisomes [56]. Such data patterns are very 
strong evidence that those proteins showing changes in nuclear abundance represent 
selective trafficking for a specific subset of cellular proteins and are not a 
consequence of contamination of the nuclear preparations with other cellular 
components. How the inclusion of a conservation of mass test can be used with 
outlier analysis to select the most reliable changes in compartmental redistribution 
has been described [57]. Importantly, comparison with the results obtained for cell 
cycle arrest at the origin activation checkpoint showed that different proteins show 
nucleo-cytoplasmic trafficking, with different changes in the nucleus for specific 
proteins from cellular functional networks such as the TCA cycle, glycolysis and the 
proline regulatory axis [55,56]. That is, high specificity in the nuclear response to 
different cellular stimulations was demonstrated. In short, as predicted some years 
ago [46], evidence for the functional importance of the subcellular distribution of a 
protein can be detected by differential changes in its location under functional 
stimulation in highly enriched although not exhaustively purified subcellular 
fractions. This is crucial for detecting the functional involvement of translocating, 
but “non-permanent-resident” proteins in different subcellular locations/organelles.  
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For the response of IMR90 cells to oxidative stress or activation of DNA replication 
checkpoints, 3-4% of the monitored proteins were found to show appreciable 
changes in compartmental abundance, with changes in total abundance (St) and in 
compartmental redistribution (Sn/Sc) contributing roughly equally. Similarly, 
subcellular translocation of 4-5% of cellular proteins was observed in a genome-
wide, fluorescence based study of the response of yeast cells to hypoxia [39]. 
For MCF7 breast cancer cells, a very different pattern was observed following 
exposure to estradiol. Many more of the monitored proteins (about 20%) showed 
substantial changes. However, of 331 proteins with >2-fold changes in at least one of 
the SILAC ratios, only 5 proteins showed >2-fold changes in total abundance (St). 
For the other proteins the >2-fold change corresponded to the changes in partitioning 
of the protein between the nuclear/cytoplasmic compartments, with a strong 
preponderance of proteins showing N  C redistribution (Fig. 6). A crucial feature 
was that >2-fold changes in compartmental abundance were much more prominent 
than changes in overall abundance. Furthermore, the identities of many of these 
proteins were consistent with previous studies of estrogen receptors. For example, in 
the nucleus the ERα and ERβ receptors have been shown to interact with 498 other 
proteins, only 70 of which are common to both [60]. Of these proteins, 357 were 
detected in the MCF7 estrogen stimulation experiments: 58 proteins showed >2-fold 
decrease in nuclear abundance, and a further 76 showed appreciable nucleo-
cytoplasmic redistribution, but none of them showed >2-fold change in total 
abundance. Of the roughly 1000 proteins that are partitioned between the nucleus and 
mitochondria, 249 showed evidence of nucleus  cytoplasm redistribution upon 
exposure to estrogen. For the 134 proteins showing the most significant changes in 
nucleo-cytoplasmic distribution, investigation of the biological processes in which 
they are implicated using REACTOME [61,62] showed association with core cellular 
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processes (gene expression, the cell cycle, protein metabolism, mRNA metabolism) 
and potential changes in more specific biological processes distributed spatially over 
the cytoplasm, plasma membrane and nucleus [57]. In short, this work revealed that 
the dominant response of MCF7 breast cancer cells to estradiol is not changes in the 
total cellular abundance of proteins, but rather a massive change in their spatial 
distribution between the nucleus and cytoplasm, with indications that this influences 
functional processes at many other subcellular spatial locations. 
Dynamic Subcellular Distribution of Proteins in Normal and Pathological 
Cellular Function. 
Evidence of dynamic redistribution of proteins to and from the 
nucleus/mitochondria/cytoplasm and other subcellular locations following external 
perturbations such as environmental cues [63], cell cycle arrest [55,56], hormonal 
stimulation [64], oxidative stress [65-67], or viral infections [68-71] is increasing 
rapidly. In a model eukaryotic system, about 50% of a partially characterized yeast 
proteome (60%) showed dynamic redistribution between the cytosol and different 
organelles in response to the environmental switches [63]. There is no longer any 
doubt that dynamic, coordinated, context-dependent redistribution of multitudinous 
proteins over many subcellular locations is a central mechanism in cellular function.  
These recent studies are beginning to characterize the general nature of the 
involvement of subcellular translocation of proteins in normal cellular function. For 
example, limited perturbations of healthy cells, including yeast subjected to hypoxia 
[39] and human fibroblasts subjected to mild oxidative stress [56] or to cell cycle 
arrest at the origin activation checkpoint for DNA replication [55], have typically 
found appreciable changes for 3-5% of proteins. Changes in total cellular abundance 
and in subcellular spatial redistribution were found to be of about equal importance 
in producing the spatial partitioning of proteins over compartments that are the basis 
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of cellular response to such stimulations. At the present time, there are indications 
from studies of viral infection [12,54,68-72] and from the studies of MCF7 breast 
cancer cells [46,49,57] that strong perturbations in basal protein distributions and 
massive protein redistribution following stimulations may be characteristic of 
disease.  
Attempts to define general features of cancer [23,24,73] include uncontrolled 
proliferation and modified metabolism, especially of metabolism connected with the 
oxidative state of cells. The latter has been a focus of cancer research ever since 
Warburg [74]. The series of experiments on cell cycle arrest at the origin activation 
checkpoint [55] and response to oxidative [56] in fibroblasts as well as the response 
of MCF7 cells to estradiol stimulation thus provide a beginning to comparing protein 
redistribution in important core processes in healthy and cancerous cells. In fact, the 
series of investigations of cell cycle arrest in IMR90 human fibroblasts [55,56,75] 
were undertaken to investigate the possible use of pharmaceutical modulators of the 
CDC7-kinase in cancer therapeutics [55,56,75,76]. So far the overall indications are 
that healthy cells show strongly regulated, coordinated changes in both total 
abundance and subcellular spatial distribution of relatively small sets of proteins that 
are highly characteristic of the cellular response to specific stimulations. In contrast, 
massive changes in subcellular spatial distribution dominated much more limited 
changes in total abundance for proteins of MCF7 cells subjected to estradiol 
stimulation. In fact, estrogen receptors themselves undergo subcellular spatial 
redistribution in many functional contexts and this is known to be connected to core 
cellular processes, e.g. efflux of ERα from the nucleus is associated with repression 
of cell cycle progression and S-phase proliferation in MCF7 cells [77]. Estrogen 
receptors are targeted for proteasomal degradation through a transcription-coupled 
pathway requiring new protein synthesis [78,79] and the proteomics experiments also 
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detected major changes in proteasomes that could be coupled to estrogen receptor 
turnover as well as many other functional processes in both the nucleus and 
cytoplasm [80]. This led to suggestions that the modified metabolic properties of 
cancerous MCF7 cells may be mainly based on perturbed spatial distribution of 
proteins, that this also opens the possibility that transformation and tumorigenicity 
may also be strongly influenced by perturbed spatial distribution of proteins, and that 
refocusing on the dominant mechanism for response of breast cancer cells to 
estradiol may have important consequences for development of therapeutics [57]. 
New Challenges for Proteomics and Bioinformatics and Progress Towards 
Medical Applications. 
The high degree of spatial/functional inhomogeneity of cells and the need for 
efficient subcellular communication means that the study of dynamic spatial 
distribution of subcellular proteins is of fundamental importance to improving 
understanding of cellular processes underlying human diseases. Indeed, this 
remarkable phenomenon occurs in any kind of cell: roughly half of all subcellular 
proteins are known to translocate into another compartment to reach their functional 
location [81], while most of the ~1,000 different “resident” proteins contained in 
mitochondria are imported from the cytosol to exert their functional role [82]. 
Moreover, numerous mislocalized proteins have been associated with human 
diseases as diverse as Alzheimer’s disease or various types of cancer and aberrant 
localization of proteins has been shown to contribute to the pathogenesis of many 
human diseases [83].  
The correct assignment/quantitation of proteins in diverse subcellular compartments 
based on quantitative high-throughput proteomics data promises to shed new light on 
many biological mechanisms. Continuing advances in proteomics MS technology 
will be important [58]. However, since each protein may have multiple subcellular 
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locations and its distribution over different locations may change as a function of cell 
cycle stage, metabolic, environmental and culture conditions, measuring context-
dependent subcellular trafficking of proteins is a challenging task. For many 
subcellular organelles numerous examples of functionally important “peripheral” 
proteins are already known. This suggests that fractionation methods should be as 
simple and mild as possible and that compensatory analyses of the type exemplified 
by the subcellular spatial razor formulation are likely to be the most informative 
approach. There is also a need for improved databases that explicitly tie together 
function/location as pair relationships for individual proteins. At present databases 
such as GO obscure crucial information by neglecting this. Furthermore, the highly 
complex data that is now emerging from studies of context-dependent subcellular 
protein trafficking indicates that we should begin thinking about cellular function in 
terms of higher level cellular processes that are distributed over diverse cellular 
spatial locations and begin building models of cellular function that explicitly take 
such spatial dispersion into account. 
The development of reliable quantitative proteomics has many potential applications 
to clinical settings. In this context, great challenges for oncologists are to ensure the 
availability of early detection/diagnostic tools and to develop methods for dealing 
with the enigmatic heterogeneity within the same kind of tumour (intra-tumour 
heterogeneity). Detection and therapeutic interventions for most cancer types have 
evolved over the past century, but are still limited to localized forms of cancer and/or 
advanced stages [84]. Moreover, better detection, targeted therapeutics and 
monitoring of cancer must be linked to the underlying biological processes 
associated with the initiation, proliferation, and metastasis stages [84,85]. Finding 
ways of rational diagnosis and prognosis is not an easy target and so far often does 
not take into consideration all the advances in the research platforms, in particular, 
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genomics and proteomics. 
It is becoming more apparent that relying on global genomics information is a 
valuable asset to formulate a hypothesis, identify recognizable tissue signatures, and 
seek correlations to medical conditions, but the functional states of cells are beyond 
the scope of genomics alone. The more focussed approach of proteomics is 
complementary to genomics and can define the functional products (proteins) of the 
deregulated genes in space and time, which increases our understanding of the 
underlying biological processes [86,87]. One of the challenges but also opportunities 
faced by the comprehensive study of proteomes is that the estimated 20-30,000 
human genes can give rise to over one million different proteins with very wide 
range in orders of magnitude of abundance [88]. Moreover, transformation of cancer 
cells is associated with major changes in the functional units (proteins), thereby 
altering the protein locations, concentrations, signalling pathways, and ultimately the 
function of the cells. Protein expression, function, location and structural mapping 
are all proteomics approaches that are integral to systems biology. They can enhance 
discovery of candidate cancer biomarkers with a high degree of specificity, 
sensitivity, classification and staging, thereby aiding in standardization of targeted 
approaches to therapy [89].  
Expert commentary: “vision of the author” 
Recent advances in the characterization of the subcellular location of proteins now 
indicate that dynamic trafficking of multitudinous proteins over many subcellular 
locations is a central mechanism in cellular function. This appears to be a key feature 
in coordination of the spatially heterogeneous distribution of different cellular 
functions. In MCF7 breast cancer cells massive nuclear-cytoplasmic redistribution of 
proteins is the dominant response to stimulation with estrogen, far outweighing 
changes in total protein abundance. Many examples of proteins with different 
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functional roles in different subcellular compartments are already known and the 
number of proteins so identified is poised to grow enormously. Proteins can only 
exert functions in locations where they exist and the recent results indicate that 
subcellular redistribution of proteins is of at least equal importance to changes in 
their total abundance in achieving the changes in compartmental abundances that are 
the basis of cellular response. There is now an urgent need for global characterization 
of the dynamic subcellular partitioning of proteins for many cell types and functional 
contexts. 
Five year view: 
We expect that in the next several years there will be major improvements in 
methodology and collection of massive amounts of global data on the dynamics of 
protein location in cells. We expect that such global analysis will be essential to 
reliable integration/interpretation of the massive numbers of more conventional 
investigations of localized features of complex cellular networks. For example, 
recent global analyses of nuclear cytoplasmic trafficking in the context of oxidative 
stress [56] and of transcriptional targets of NRF2 [90] suggest new interpretations of 
the crucial role(s) of NRF2 in oxidative stress responses that are linked to heme/iron 
homeostasis or to proteins that contain heme/iron as cofactors and that were largely 
missed by inference from large numbers of conventional experiments [56]. Similarly, 
results on trafficking in the context of response of MCF7 cells to estrogen have 
suggested that nuclear hormone receptors may be master integrators of spatial 
coordination in cells [57]. It is increasingly apparent that spatial coordination is a key 
aspect of cellular function in both healthy and disease states. We expect that 
differential network analysis [91] of global features of spatial control will begin to 
define high level functional processes/networks that are spatially dispersed across 
many cellular locations. Integration of such information with genomic, 
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transciptomic, and metabolomic information will be crucial to unravelling the 
enormously complicated complex adaptive systems that cells represent and to 
exploiting the information in medical and other applications.  
Key issues:  
1. Analytical methods that can follow dynamic subcellular redistribution of proteins 
have become available, with a prominent role for MS-based proteomics. 
2. Large proportions of cellular proteins are distributed to multiple subcellular 
locations and may have different functions in those locations. 
3. The subcellular spatial distribution of proteins is dynamic, changes with cellular 
state and is a central mechanism of cellular function. Nuclear-cytoplasmic trafficking 
of proteins is the dominant response for MCF7 cells exposed to estrogen. 
4. Present evidence suggests that changes in subcellular location of proteins are of at 
least equal importance to changes in total protein abundance in cellular response to 
environmental cues, cell cycle stages, hormonal stimulation, oxidative stress, etc.  
5. Dynamic protein redistribution provides a means to coordinate function over the 
spatial inhomogeneity of cells. 
6. Coordinated changes in abundance/distribution of relatively small sets of proteins 
seem to be characteristic of cellular response to specific perturbations in healthy 
cells. 
7. Early evidence from studies of viral infection and breast cancer cells suggests that 
disregulated cellular spatial control may be a feature of disease states. 
8. New high level models of cellular function that include dispersion of functional 
systems over multiple subcellular locations and include dynamic redistribution of 
proteins need to be constructed. 
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9. The information needs to be integrated with genomics, transcriptomics and 
metabolomics to obtain integrated, comprehensive models of cellular function.  
10. These new concepts of cellular function will offer many opportunities in medical 
diagnostics and therapeutics as well as other applications.  
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Figure 1.  Workflow for subcellular analysis with quantitative shotgun proteomics. 
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Figure 2. Proteomics approach to assess global static subcellular distribution of proteins. (A) 
Sucrose gradient fractionation for different organellar compartments (cytoplasm - C, plasma 
membrane - P, endoplasmic reticulum – ER, mitochondrion – M). (B) Proteins from each 
compartment are analysed by MS and a set of {protein, fraction, spectral counts} data points 
is assembled. Proteins identified by only one peptide or with few spectral counts are filtered 
out. (C) Hierarchical clustering and heat map for the amount of each protein in the four 
compartments. Individual proteins are represented by a single row, each fraction is 
represented by a single column and each cell represents the abundance of a protein in a 
compartment. The color scale is for normalized relative abundance from 6.0 (red) to 1.0 
(yellow) to 0.0 (blue, not detected)  (D) Quantitative abundances (relative) for the distribution 
of different proteins over the four compartments indicate the distributions are not due to 
artefacts in the sucrose gradient fractionation. The data is used to calculate the mole fraction 
of each protein in the four compartments. (E) Primary mole fractions vs secondary mole 
fractions for proteins with a primary location and 1 (green), 2 (blue), or 3 (red) secondary 
locations 
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Figure 3. Alternative approaches to validation of results: (A) Demonstration of reproducibility of 
fractionation in three replicates by Western blotting of proteins contained in a cellular total lysate (T) 
or in nuclear (N), mitochondrial (M) and cytoplasmic (C) subcellular preparations. (B) Western blot 
[49], and (C) immunofluorescence [56] analysis to confirm subcellular localization obtained by MS 
analysis. 
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Figure 4. Three-dimensional data representation for the subcellular spatial razor model. (A) For the 
orthogonal 3D space {Sn/St, Sc/St, St}, the theoretical distribution plane {Sn/St, Sc/St} for different 
values of fu (the fraction of protein in the nucleus in the unstimulated cells) as the fraction of the 
protein in the nucleus in the stimulated cells (fs) varies over 0 < fs < 1. (B) Six proteins plotted in the 
3D space {Sn/St, Sc/St, St} for estrogen stimulated/unstimulated MCF-7 cells showing scatter over the 
replicates [57]. (C) Proteins or protein complexes plotted in the 3D space {Sn/St, Sc/St, St} for TBP-
induced oxidative stress of human fibroblasts [56]. In panels B and C the axis perpendicular to the 
page is color coded for changes in total abundance (St). The orange bounding lines show 2-fold 
changes in (Sn/Sc). 
 35 
 
 
 
 
-2.5	
-2	
-1.5	
-1	
-0.5	
0	
0.5	
1	
1.5	
2	
2.5	
1	 10	 100	 1000	
lo
g 2
(	S
n	
	/
	S
t	
)	
average	number	of	SILAC	ra o	counts		
mitochondrion	in	nuclear	frac on	
		M	&	N	(147)	 		M	(224)	
ETHE1	
SYNE2	
HK1	
TUFM	
MDH2	
PRDX5	
BAX	
FEN1	
OAT	
ETFB	
GPD2	
CYB5A	
PHB	
average	log2(Sn	/	St)	=	0.002	371	proteins	
0	
50	
100	
150	
200	
250	
300	
-1	 0	 1	
num
ber	of	proteins	
log2(	Sn	/	St	)	
sca er	
 
 
 
 
 
Figure 5. Analysis of the enrichment/purity of the nuclear fraction. Left: log2(Sn/St) = 
log2(fs/fu) as a function of the average number of ratio counts over the nucleus and 
total data sets for proteins with GO annotation to mitochondria and nucleus (red, 143 
proteins) or to mitochondria but not nucleus (blue, 218 proteins). Right: number of 
proteins versus log2(fs/fu). 
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Figure 6. Three-dimensional plot for 331 proteins with significant changes upon 
estrogen stimulation of MCF7 cells. The legend (lower left) shows the symbol 
coding for >2-fold changes only in Sn, only in Sc, in both Sn and Sc, for Sn/Sc only, 
and for St. Increases/decreases are color coded (upper right legend). 
 
